Cargando…

Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification

Extrahepatic cholangiocarcinoma (ECC) is an uncommon and devastating malignancy that mainly consists of adenocarcinoma. Adenosquamous carcinoma is a rare histologic type and accounts for 2–5% of ECC. It reports that 3.6–8.5% of ECC patients carry Her-2 amplification. A 45-year-old woman was admitted...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Ye, Li, Xiaofen, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983672/
https://www.ncbi.nlm.nih.gov/pubmed/33763343
http://dx.doi.org/10.3389/fonc.2021.538328
_version_ 1783667940430708736
author Hong, Ye
Li, Xiaofen
Cao, Dan
author_facet Hong, Ye
Li, Xiaofen
Cao, Dan
author_sort Hong, Ye
collection PubMed
description Extrahepatic cholangiocarcinoma (ECC) is an uncommon and devastating malignancy that mainly consists of adenocarcinoma. Adenosquamous carcinoma is a rare histologic type and accounts for 2–5% of ECC. It reports that 3.6–8.5% of ECC patients carry Her-2 amplification. A 45-year-old woman was admitted to our hospital because of jaundice. Abdominal computerized tomography (CT) suggested extrahepatic biliary tract mass. The patient received surgery and pathological examination confirmed adenosquamous carcinoma. Fluorescence in Situ Hybridization (FISH) and Next-generation sequencing showed the tumor had Her-2 amplification. One month after the operation, CT demonstrated distant lymph nodes metastases (cT3N1M1, stage IV). The patient received gemcitabine and cisplatin combined with targeted therapy of trastuzumab. After three cycles of treatment, the evaluation of response was stable disease (SD). The progression-free survival of 1st line treatment (PFS1) reached 5 months with five cycles of treatment. After progression, the patient received three cycles of albumin-bound paclitaxel combined with S-1 and trastuzumab and concurrent chemoradiotherapy (S-1) because of serious backache. Now, the disease is stable, and the PFS of 2nd line treatment (PFS2) has reached 7 months.
format Online
Article
Text
id pubmed-7983672
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79836722021-03-23 Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification Hong, Ye Li, Xiaofen Cao, Dan Front Oncol Oncology Extrahepatic cholangiocarcinoma (ECC) is an uncommon and devastating malignancy that mainly consists of adenocarcinoma. Adenosquamous carcinoma is a rare histologic type and accounts for 2–5% of ECC. It reports that 3.6–8.5% of ECC patients carry Her-2 amplification. A 45-year-old woman was admitted to our hospital because of jaundice. Abdominal computerized tomography (CT) suggested extrahepatic biliary tract mass. The patient received surgery and pathological examination confirmed adenosquamous carcinoma. Fluorescence in Situ Hybridization (FISH) and Next-generation sequencing showed the tumor had Her-2 amplification. One month after the operation, CT demonstrated distant lymph nodes metastases (cT3N1M1, stage IV). The patient received gemcitabine and cisplatin combined with targeted therapy of trastuzumab. After three cycles of treatment, the evaluation of response was stable disease (SD). The progression-free survival of 1st line treatment (PFS1) reached 5 months with five cycles of treatment. After progression, the patient received three cycles of albumin-bound paclitaxel combined with S-1 and trastuzumab and concurrent chemoradiotherapy (S-1) because of serious backache. Now, the disease is stable, and the PFS of 2nd line treatment (PFS2) has reached 7 months. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7983672/ /pubmed/33763343 http://dx.doi.org/10.3389/fonc.2021.538328 Text en Copyright © 2021 Hong, Li and Cao http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Hong, Ye
Li, Xiaofen
Cao, Dan
Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification
title Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification
title_full Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification
title_fullStr Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification
title_full_unstemmed Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification
title_short Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification
title_sort case report: trastuzumab treatment in adenosquamous carcinoma of the extrahepatic biliary tract with her-2 amplification
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983672/
https://www.ncbi.nlm.nih.gov/pubmed/33763343
http://dx.doi.org/10.3389/fonc.2021.538328
work_keys_str_mv AT hongye casereporttrastuzumabtreatmentinadenosquamouscarcinomaoftheextrahepaticbiliarytractwithher2amplification
AT lixiaofen casereporttrastuzumabtreatmentinadenosquamouscarcinomaoftheextrahepaticbiliarytractwithher2amplification
AT caodan casereporttrastuzumabtreatmentinadenosquamouscarcinomaoftheextrahepaticbiliarytractwithher2amplification